Polymyositis
53
7
9
33
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
11 trials with published results (21%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.5%
4 terminated out of 53 trials
89.2%
+2.7% vs benchmark
13%
7 trials in Phase 3/4
33%
11 of 33 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 33 completed trials
Clinical Trials (53)
Environmental Risk Factors for the Anti-synthetase Syndrome
Adult and Juvenile Myositis
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties
Add-on Intravenous Immunoglobulins in Early Myositis
Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases
Rheumatology Patient Registry and Biorepository
MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis
A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.
CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory Polymyositis or Dermatomyositis
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
Study of M5049 in DM and PM Participants (NEPTUNIA)
A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases
Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)